NEWTON CHARLES W. (Chief Financial Officer) sold 8.7% of their position (1.45K shares) of LYELL IMMUNOPHARMA, INC. on the open market
Open‑market sale worth $15.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/22/2025ACC: 0001415889-25-022741
Officer· Chief Financial Officer
Since Jun 2021
+6.55K
Net shares
Net buyer
$15.3K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
8K acquired · 1.45K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+8K
Price / share
—
Trade value
—
% of position
91.3%
8/20/2025
8.76K→16.76K
Common Stock
Direct
Shares
−1.45K
Price / share
$10.54
Trade value
$15.32K
% of position
8.7%
8/21/2025
16.76K→15.31K
Total
Net shares
+6.55K
Net value
-$15.32K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/20/2025 | A · Award | +8K | — | — | 91.3% | 8.76K | 16.76K |
| Common Stock Direct | 8/21/2025 | S · Sale | −1.45K | $10.54 | $15.32K | 8.7% | 16.76K | 15.31K |
| Total | +6.55K | -$15.32K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned10K
Total
10K indirect10K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 10K | Indirect |
| Total | 10K | 10K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported